Novel tryptamine oral film formulation
AssigneeIntelgenx Corp.
InventorsMobarik BILAL, Billal TIR, Nadine PAIEMENT
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to oral film formulations, which provide a tryptamine active agent. The disclosure more particularly relates to oral film formulations with improved buccal absorption of tryptamine active agents. The present disclosure also relates to formulations and methods for treatment of various symptoms in a patient, such as the treatment of mental health conditions.
Claims24
An oral film formulation comprising an active agent selected from psilocybin, psilocin, norpsilocin, bufotenin, bufotenidine, baeocystin, norbaeocystin, and aeruginascin, and salts thereof, and combinations thereof, a penetration enhancer, an acidifying agent, and a plasticizer, wherein the surface pH range of the oral film formulation is preferably between 1.5 and 5.
(canceled)
(canceled)
(canceled)
A method of using an acidifying agent and penetration agent for enhancing permeation of psilocybin, psilocin, norpsilocin, bufotenin, bufotenidine, baeocystin, norbaeocystin, and aeruginascin, and salts thereof, and combinations thereof, wherein the method comprises administering the oral film formulation buccally.
An oral film formulation comprising an active agent, a penetration enhancer, an acidifying agent and a plasticizer, wherein the pH range of the oral film formulation is preferably between 1.5 and 5, and wherein the active agent is a tryptamine.
(canceled)
Dependencies are inferred from the claim text.